MedSchool: Ace Your OSCEsThe Medical Company
GET - On the App Store
Drug Guide


    May be used in patients with T790M mutations which would otherwise confer resistance to other generations of EGFR inhibitors
    • Mechanism of Action
    • Inhibits epidermal growth factor receptor (EGFR), a transmembrane amino acid receptor tyrosine kinase found in approximately 15% of non small cell lung cancers.
      EGFR mutations affect downstream signalling pathways resulting in cell proliferation
      Inhibition of these receptors disrupts this proliferation pathway.

Clinical Use

    • Indication
    • Advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutation
    • Adverse Effects
Want more info like this?
  • Your electronic clinical medicine handbook
  • Guides to help pass your exams
  • Tools every medical student needs
  • Quick diagrams to have the answers, fast
  • Quizzes to test your knowledge
Sign Up Now